mAbx01 (etanercept biosimilar) / mAbxience - LARVOL DELTA

The infectious profiles of biotherapeutic agents in an Algerian population (WCO-IOF-ESCEO 2016) - P=NA, N=107; “The products used were adalimumab (33.6 %) etanercept (29 %) rituximab (13 %) tocilizumab (13 %) and infliximab (11.2 %)…Infections events are more common in anti-TNFα treated patients than those on rituximab or tocilizumab.”

Clinical data • Biosimilar • Immunology